1:41 PM
 | 
Feb 11, 2019
 |  BC Extra  |  Company News

3SBio gains Verseau's macrophage checkpoint modulators for cancer

With a deal to license macrophage checkpoint modulators, 3SBio Inc. (HKSE:1530) is bypassing the standard roster of T cell targets and jumping to the next wave of immuno-oncology targets. The company is gaining exclusive access...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >